UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors

Methods in molecular biology (Clifton, N.J.), 2018, Vol.1709, p.423

2018

Volltextzugriff (PDF)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

Nature communications, 2021-06, Vol.12 (1), p.3880-3880, Article 3880

2021

Volltextzugriff (PDF)

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Journal of clinical oncology, 2013-06, Vol.31 (17), p.2128-2135

2013

Volltextzugriff (PDF)

Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development

Cell stress & chaperones, 2018-07, Vol.23 (4), p.467-482

2018

Volltextzugriff (PDF)

Stressing the Development of Small Molecules Targeting HSP90

Clinical cancer research, 2014-01, Vol.20 (2), p.275-277

2014

Volltextzugriff (PDF)

Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity

Oncotarget, 2017-02, Vol.8 (6), p.10425-10436

2017

Volltextzugriff (PDF)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

The lancet oncology, 2018-02, Vol.19 (2), p.207-215

2018

Volltextzugriff (PDF)

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Medical oncology (Northwood, London, England), 2017-06, Vol.34 (6), p.103, Article 103

2017

Volltextzugriff (PDF)

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (14), p.4022-4035

2018

Volltextzugriff (PDF)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation

Scientific reports, 2018-05, Vol.8 (1), p.6976-13, Article 6976

2018

Volltextzugriff (PDF)

Threonine 22 Phosphorylation Attenuates Hsp90 Interaction with Cochaperones and Affects Its Chaperone Activity

Molecular cell, 2011-03, Vol.41 (6), p.672-681

2011

Volltextzugriff (PDF)

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2020-12, Vol.25 (12), p.1013-e1824

2020

Volltextzugriff (PDF)

Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4), p.902-911

2016

Volltextzugriff (PDF)

Hsp90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase-stimulating cochaperone Aha1

Nature communications, 2019-06, Vol.10 (1), p.2574-2574, Article 2574

2019

Volltextzugriff (PDF)

Asymmetric Hsp90 N Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors

Molecular cell, 2014-01, Vol.53 (2), p.317-329

2014

Volltextzugriff (PDF)

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature communications, 2024-03, Vol.15 (1), p.2805-2805, Article 2805

2024

Volltextzugriff (PDF)

Immunotherapy: a new treatment paradigm in bladder cancer

Current opinion in oncology, 2017-05, Vol.29 (3), p.184-195

2017

Volltextzugriff (PDF)

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants

PloS one, 2015-10, Vol.10 (10), p.e0141786-e0141786

2015

Volltextzugriff (PDF)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.197-8, Article 197

2019

Volltextzugriff (PDF)

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Scientific reports, 2017-03, Vol.7 (1), p.201-201, Article 201

2017

Volltextzugriff (PDF)

Structural and functional complexity of HSP90 in cellular homeostasis and disease

Nature reviews. Molecular cell biology, 2023-11, Vol.24 (11), p.797-815

2023

Volltextzugriff (PDF)

An Hsp90 co-chaperone protein in yeast is functionally replaced by site-specific posttranslational modification in humans

Nature communications, 2017-05, Vol.8 (1), p.15328-15328, Article 15328

2017

Volltextzugriff (PDF)

Englerin A Stimulates PKCθ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality

Cancer cell, 2013-02, Vol.23 (2), p.228-237

2013

Volltextzugriff (PDF)

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Japanese journal of clinical oncology, 2023-01, Vol.53 (1), p.4-15

2023

Volltextzugriff (PDF)

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2011-07, Vol.108 (29), p.11878-11883

2011

Volltextzugriff (PDF)

1 – 25 von 276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(251)
Mit Volltextzugriff
(249)

Publikationsform

Sprache

Englisch
(276)
Japanisch
(32)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development

Stressing the Development of Small Molecules Targeting HSP90

Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation

Threonine 22 Phosphorylation Attenuates Hsp90 Interaction with Cochaperones and Affects Its Chaperone Activity

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild‐Type, Advanced Triple‐Negative Breast Cancer

Effects of Anticancer Drugs on Chromosome Instability and New Clinical Implications for Tumor-Suppressing Therapies

Hsp90 middle domain phosphorylation initiates a complex conformational program to recruit the ATPase-stimulating cochaperone Aha1

Asymmetric Hsp90 N Domain SUMOylation Recruits Aha1 and ATP-Competitive Inhibitors

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Immunotherapy: a new treatment paradigm in bladder cancer

Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Structural and functional complexity of HSP90 in cellular homeostasis and disease

An Hsp90 co-chaperone protein in yeast is functionally replaced by site-specific posttranslational modification in humans

Englerin A Stimulates PKCθ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Suchergebnisse filtern